Αναζήτηση Δραστικών

EPOETIN ALFA (RECOMBINANT)

Εμπορικές Ονομασίες

  • RETACRIT
    Μορφές: INJ.SOL
    Μορφές:
  • EPREX
    Μορφές: INJ.SOL
  • EPORATIO
    Μορφές: INJ.SO.PFS
    Μορφές:
  • BINOCRIT
    Μορφές: INJ.SO.PFS
    Μορφές:
    Μορφές: INJ.SOL
  • DRUGBANK - Epoetin alfa
  • indication:

    For treatment of anemia (from renal transplants or certain HIV treatment)

  • pharmacology:

  • mechanism:

    Binding of erythropoietin to the erythropoietin receptor leads to receptor dimerization, which facilitates activation of JAK-STAT signaling pathways within the cytosol. Activated STAT (signal transducers and activators of transcription) proteins are then translocated to the nucleus where they serve as transcription factors which regulate the activation of specific genes involved in cell division or differentiation.

  • toxicity:

  • absorprion:

  • halflife:

  • roouteelimination:

  • volumedistribution:

  • clearance:

    * 20.2 +/- 15.9 mL/h/kg [150 Units/kg SC TIW, Week 1 when anemic cancer patients were receiving chemotherapy] * 23.6 +/- 9.5 mL/h/kg [150 Units/kg SC TIW, Week 3 when anemic cancer patients were not receiving chemotherapy] * 9.2 +/- 4.7 mL/h/kg [40,000 Units/kg SC TIW, Week 1 when anemic cancer patients were receiving chemotherapy] * 13.9 +/- 7.6 mL/h/kg [40,000 Units/kg SC TIW, Week 3 when anemic cancer patients were not receiving chemotherapy]